Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC

被引：0
|
作者：
Martin Jimenez, M. [1 ]
Hilz, S. [2 ]
Collier, A. [2 ]
Chibly, A. [3 ]
Sohn, J. [4 ]
Bardia, A. [5 ]
Lim, E. [6 ]
Mac Gregor, M. Chavez [7 ]
Martinalbo, J. [8 ]
Perez-Moreno, P. D. [9 ]
Moore, H. M. [2 ]
机构：
[1] Univ Complutense, Hosp Gregorio Maranon, GEICAM, CIBERONC, Madrid, Spain
[2] Genentech Inc, Oncol Biomarker Dev, South San Francisco, CA USA
[3] Genentech Inc, Bioinformat, South San Francisco, CA USA
[4] Yonsei Univ, Dept Internal Med, Seoul, South Korea
[5] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[6] Univ New South Wales, Garvan Inst Med Res, St Vincents Clin Sch, Darlinghurst, NSW, Australia
[7] Univ Texas MD Anderson Canc Ctr, Div Canc Prevent & Populat Sci, Dept Hlth Serv Res, Houston, TX USA
[8] F Hoffmann La Roche Ltd, Oncol Drug Dev, Basel, Switzerland
[9] Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
413P
引用
收藏
页码：S356 / S357
页数：2
相关论文
共 50 条
  • [1] Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC)
    Collier, Ann
    Mac Gregor, Mariana Chavez
    Hilz, Stephanie
    Bardia, Aditya
    Sohn, Joohyuk
    Martin, Miguel
    Lim, Elgene
    Martinalbo, Jorge
    Perez-Moreno, Pablo Diego
    Moore, Heather M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
    Martin, Miguel
    Lim, Elgene
    Chavez-MacGregor, Mariana
    Bardia, Aditya
    Wu, Jiong
    Zhang, Qingyuan
    Nowecki, Zbigniew
    Cruz, Felipe Melo
    Safin, Rustem
    Kim, Sung-Bae
    Schem, Christian
    Montero, Alberto J.
    Khan, Sarah
    Bandyopadhyay, Reeti
    Moore, Heather M.
    Shivhare, Mahesh
    Patre, Monika
    Martinalbo, Jorge
    Roncoroni, Laura
    Perez-Moreno, Pablo Diego
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (18) : 2149 - 2160
  • [3] Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer
    Collier, Ann
    Bardia, Aditya
    Sohn, Joo Hyuk
    Lim, Elgene
    Chavez, Marianna
    Martin, Miguel
    Martinalbo, Jorge
    Perez-Moreno, Pablo
    Moore, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [4] ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer
    Bailleux, Caroline
    Bachelot, Thomas
    Bidard, Francois-Clement
    Hardy-Bessard, Anne-Claire
    Bieche, Ivan
    Pradines, Anne
    Clatot, Florian
    Rouge, Thibault De La Motte
    Canon, Jean-Luc
    Pistilli, Barbara
    Chang, Kyle
    Quinn, Katie J.
    Gustafson, Heather L.
    Dalenc, Florence
    Foa, Cyril
    Ammarguellat, Hanifa
    Bernard-Marty, Chantal
    Lucas, Brigitte
    Barthier, Sophie
    Lorchel, Fabrice
    Gisserot, Olivier
    Arnould, Laurent
    Mauduit, Marjorie
    Lemonnier, Jerome
    Berger, Frederique
    Delaloge, Suzette
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [5] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
    Mayer, Erica L.
    Tolaney, Sara M.
    Brufsky, Adam
    Gradishar, William John
    Jhaveri, Komal L.
    Martin, Miguel
    Moscetti, Luca
    Schneeweiss, Andreas
    Vidal, Gregory A.
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
    Martin, Miguel
    Lim, Elgene
    Mac Gregor, Mariana Chavez
    Shivhare, Mahesh
    Ross, Graham
    Patre, Monika
    Roncoroni, Laura
    Louka, Maria
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [9] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [10] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
12345